60 related articles for article (PubMed ID: 8764333)
1. Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure.
Begany DP; Carcillo JA; Herzer WA; Mi Z; Jackson EK
J Pharmacol Exp Ther; 1996 Jul; 278(1):37-41. PubMed ID: 8764333
[TBL] [Abstract][Full Text] [Related]
2. Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.
Carcillo JA; Herzer WA; Mi Z; Thomas NJ; Jackson EK
J Pharmacol Exp Ther; 1996 Dec; 279(3):1197-204. PubMed ID: 8968341
[TBL] [Abstract][Full Text] [Related]
3. Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Jackson EK
J Pharmacol Exp Ther; 2001 Jan; 296(1):168-74. PubMed ID: 11123377
[TBL] [Abstract][Full Text] [Related]
4. Lipopolysaccharide-induced acute renal failure in conscious rats: effects of specific phosphodiesterase type 3 and 4 inhibition.
Jonassen TE; Graebe M; Promeneur D; Nielsen S; Christensen S; Olsen NV
J Pharmacol Exp Ther; 2002 Oct; 303(1):364-74. PubMed ID: 12235272
[TBL] [Abstract][Full Text] [Related]
5. Reversal of acute tacrolimus-induced renal vasoconstriction by theophylline in rats.
McLaughlin GE; Kashimawo LA; Steele BW; Kuluz JW
Pediatr Crit Care Med; 2003 Jul; 4(3):358-62. PubMed ID: 12831420
[TBL] [Abstract][Full Text] [Related]
6. Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs.
Tanahashi M; Hara S; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S
J Pharmacol Exp Ther; 1999 Jun; 289(3):1533-8. PubMed ID: 10336549
[TBL] [Abstract][Full Text] [Related]
7. Imaging of cAMP-specific phosphodiesterase-IV: comparison of [11C]rolipram and [11C]Ro 20-1724 in rats.
Lourenco CM; DaSilva JN; Warsh JJ; Wilson AA; Houle S
Synapse; 1999 Jan; 31(1):41-50. PubMed ID: 10025682
[TBL] [Abstract][Full Text] [Related]
8. Characterization of renal ecto-phosphodiesterase.
Jackson EK; Ren J; Zacharia LC; Mi Z
J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo.
Tofovic SP; Zacharia LC; Carcillo JA; Jackson EK
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):787-92. PubMed ID: 11022970
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle.
Halene TB; Siegel SJ
J Pharmacol Exp Ther; 2008 Jul; 326(1):230-9. PubMed ID: 18420599
[TBL] [Abstract][Full Text] [Related]
11. Effect of the type IV phosphodiesterase inhibitor Ro 20-1724 on catecholamine-induced alterations in regional vascular resistance and regional blood flow.
Thomas NJ; Herzer WA; Carcillo JA; Jackson EK
J Cardiovasc Pharmacol; 1998 Jun; 31(6):840-53. PubMed ID: 9641468
[TBL] [Abstract][Full Text] [Related]
12. Influence of pentoxifylline and related analogues in endotoxemic renal failure.
Berens KL; Langston JD; Wasan KM; Luke DR
Circ Shock; 1991 Jul; 34(3):344-8. PubMed ID: 1884436
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterases in the rat renal vasculature.
Jackson EK; Mi Z; Carcillo JA; Gillespie DG; Dubey RK
J Cardiovasc Pharmacol; 1997 Dec; 30(6):798-801. PubMed ID: 9436820
[TBL] [Abstract][Full Text] [Related]
14. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
15. Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition.
Millar CG; Thiemermann C
Br J Pharmacol; 1997 Aug; 121(8):1824-30. PubMed ID: 9283724
[TBL] [Abstract][Full Text] [Related]
16. Magnesium supplementation combined with N-acetylcysteine protects against postischemic acute renal failure.
de Araujo M; Andrade L; Coimbra TM; Rodrigues AC; Seguro AC
J Am Soc Nephrol; 2005 Nov; 16(11):3339-49. PubMed ID: 16177005
[TBL] [Abstract][Full Text] [Related]
17. Aminoguanidine attenuates endotoxin-induced mesenteric vascular hyporeactivity.
Kavuklu B; Iskit AB; Guc MO; Ilhan M; Sayek I
Br J Surg; 2000 Apr; 87(4):448-53. PubMed ID: 10759741
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion.
Nitescu N; Ricksten SE; Marcussen N; Haraldsson B; Nilsson U; Basu S; Guron G
Nephrol Dial Transplant; 2006 May; 21(5):1240-7. PubMed ID: 16390850
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate.
Shim HJ; Kim YC; Kim EJ; Kim DG; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2004 Apr; 25(3):137-42. PubMed ID: 15083502
[TBL] [Abstract][Full Text] [Related]
20. Endotoxin releases a substance from the aorta that dilates an isolated arteriole by up-regulating INOS.
Viol AW; Prewitt RL; Doviak M; Britt LD
J Surg Res; 2005 Aug; 127(2):106-11. PubMed ID: 15921695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
